SHOULD WE MEASURE ROUTINELY OXIDIZED AND SMALL DENSE LOW-DENSITY LIPOPROTEINS IN SUBJECTS WITH TYPE 2 DIABETES?

Manfredi Rizzo, Kaspar Berneis, Spyridon Koulouris, Socrates Pastromas,
Giovam Battista Rini, Dimitrios Sakellariou, Antonis Manolis

► To cite this version:

Manfredi Rizzo, Kaspar Berneis, Spyridon Koulouris, Socrates Pastromas, Giovam Battista Rini, et al.. SHOULD WE MEASURE ROUTINELY OXIDIZED AND SMALL DENSE LOW-DENSITY LIPOPROTEINS IN SUBJECTS WITH TYPE 2 DIABETES?. International Journal of Clinical Practice, 2010, 64 (12), pp.1632. 10.1111/j.1742-1241.2010.02378.x . hal-00574837

HAL Id: hal-00574837

<https://hal.science/hal-00574837>

Submitted on 9 Mar 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SHOULD WE MEASURE ROUTINELY OXIDIZED AND SMALL DENSE LOW-DENSITY LIPOPROTEINS IN SUBJECTS WITH TYPE 2 DIABETES?

Journal:	<i>International Journal of Clinical Practice</i>
Manuscript ID:	IJCP-01-10-0010.R1
Manuscript Type:	Systematic Review
Date Submitted by the Author:	16-Feb-2010
Complete List of Authors:	Rizzo, Manfredi; University of Palermo, Department of Clinical Medicine Berneis, Kaspar Koulouris, Spyridon Pastromas, Socrates Rini, Giovam Battista Sakellariou, Dimitrios Manolis, Antonis
Specialty area:

SHOULD WE MEASURE ROUTINELY OXIDIZED AND SMALL DENSE LOW-DENSITY LIPOPROTEINS IN SUBJECTS WITH TYPE 2 DIABETES?

Manfredi Rizzo (1)*, Kaspar Berneis (2,3)*, Spyridon Koulouris (4), Socrates

Pastromas (4)*, **Giovam Battista Rini (1)**, Dimitrios Sakellariou (4), Antonis S. Manolis (4)

(1) Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy;

(2) Division of Endocrinology, Diabetes & Clinical Nutrition, University Hospital Zurich, Switzerland;

(3) Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland;

(4) First Department of Cardiology, Evagelismos Hospital, Athens, Greece.

*These authors contributed equally to the present work.

Running title: Oxidized and small, dense LDL in diabetes

Correspondence to:

Manfredi Rizzo, MD, PhD

Dipartimento di Medicina Clinica e delle Patologie Emergenti

Universita' di Palermo

Via del Vespro, 141 - 90127 - Palermo - Italy

Ph. and Fax: +39 (091) 6552945; e-mail: mrizzo@unipa.it

DISCLOSURES: All authors have nothing to disclosure.

ABSTRACT

Beyond LDL-cholesterol concentrations, in recent years several clinical studies have shown that both oxidized and small, dense low-density lipoproteins (LDL) have a strong predictive role for the presence of vascular atherosclerosis. These two lipid parameters seem to have a synergistic impact on cardiovascular risk, with a greater importance in patients at higher-risk, such as those with type-2 diabetes. Increased levels of oxidized and small, dense LDL levels are a feature of diabetic dyslipidemia and small, dense LDL have been shown to be good predictor of future cardiovascular events, at both univariate and multivariate analyses. On the other hand, although the association of oxidized LDL with surrogate markers of atherosclerosis is consistent, the correlation with hard clinical end points seems to be smaller. Yet, measurement of these two lipid parameters has not been widely used in daily practice due to the limited availability of clinical data and to methodological problems: lack of availability of easy, cheap and reproducible essays for measurement of oxidized and, particularly, small, dense LDL have reduced their assessment in large clinical end-points trials. However, on the basis of available data, the therapeutic modulation of small, dense LDL is significantly associated with reduced cardiovascular risk, even after adjustment for confounding factors. In conclusion, the routine measurement of oxidized and small, dense LDL in patients with type-2 diabetes cannot be recommended in daily clinical practice so far; yet, their measurement is strongly encouraged, in order to better understand their role on the cardiovascular risk of patients with type-2 diabetes.

Key words: diabetes; oxidized LDL; small, dense LDL; cardiovascular risk; prevention.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

How did you gather, select and analyze the info you considered in your review?

We searched for and reviewed all the available evidence in a systematic way. A literature search (by Medline and Scopus) was performed using the following headings: “diabetes”, “LDL”, “lipoproteins”, “oxidized” “small, dense”, “size”, “subfractions”, “subclasses”, and “therapy” up to 30 December 2009. The authors also manually reviewed the references of selected articles for any pertinent material.

What is the take-home message for the clinician?

Beyond LDL-cholesterol concentrations, oxidized and small, dense LDL seems to have a synergistic impact on the cardiovascular risk of subjects with type-2 diabetes. Although the routine measurement of these two lipid parameters in **these** patients cannot be recommended **so far**, their measurement is strongly encouraged, in order to better understand their role on cardiovascular risk of patients with type-2 diabetes.

1. Introduction

Diabetes mellitus (DM) and its vascular complications represent a significant and growing problem in the Western World. Patients with type-2 diabetes develop more frequently accelerated atherosclerosis compared to the general population and mortality for ischemic heart disease is common [1]. Oxidative stress, as a consequence of the combined effect of various cardiovascular risk factors such as dyslipidemia, hypertension and DM, plays a crucial role in the atherogenic process [2]. The increase in reactive oxygen species leads to the formation of oxidized (ox) low-density lipoproteins (LDL). Nowadays, there is enough evidence supporting the hypothesis that oxLDL are highly immunogenic and atherogenic. Reactive oxygen species (ROS) are generated through several metabolic pathways. These cascades act as modifiers in fatty acids, lipoproteins and amino acids, resulting in the formation of atherogenic particles such as oxLDL [3].

Native LDL particles are characterized by heterogeneity in their physical properties like size and density. Based on various analytical methods such as gradient gel electrophoresis, high-performance gel-filtration chromatography and nuclear magnetic resonance spectroscopy, subclasses of larger, more buoyant or smaller and more dense LDL have been identified. These small, dense LDL particles are more likely to form oxLDL, are less readily cleared and highly atherogenic [4]. Insulin resistance, which is central in type-2 DM, leads to high serum levels of very low density lipoproteins (VLDL) enriched in triglycerides, which are metabolized predominantly to small dense LDL. Thus, small dense LDL particles are an integral part of diabetic dyslipidemia that is also characterized by increased triglyceride and reduced high density lipoproteins (HDL)-cholesterol concentrations [5].

Clinical studies have shown that both small, dense LDL and oxLDL may have a distinct predictive role for the presence of vascular atherosclerosis in patients with type-2 DM. However, measurement of these two lipid parameters has not been widely used in daily practice probably due to the limited availability of clinical data and to methodological problems. The aim of the present

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

article is to discuss the most recent clinical evidence about the role of small dense LDL and oxLDL in the development and progression of atherosclerosis and cardiovascular diseases, mainly in patients with type-2 DM. In order to do so, a systematic literature search (by Medline and Scopus) was performed using the following headings: “diabetes”, “LDL”, “lipoproteins”, “oxidized” “small, dense”, “size”, “subfractions”, “subclasses”, and “therapy” up to 30 December 2009. The authors also manually reviewed the references of selected articles for any pertinent material.

2. Oxidation of LDL

LDL can be oxidized by metal ions (e.g. Cu^{+2}), lipoxygenases, myeloperoxidase and reactive nitrogen species. Under oxidative stress, lipid molecules containing polyunsaturated fatty acids in LDL are easily oxidized. *In vitro*, this process includes three phases and a number of changes in lipid composition occur, including the substantial loss of free and esterified cholesterol and the generation of oxidation products, such as oxysterols [6]. Oxysterols seems to have many potent and diverse effects *in vitro*, several of which may be important in the atherosclerosis process. The initial phase (lag phase) includes the consumption of the endogenous LDL antioxidants (e.g. vitamin E). The second phase (propagation phase) includes the rapid oxidation of esterified fatty acids to lipid hydroperoxides and up to 90% of the steryl ester acyl groups are modified. In details, in mildly oxidized LDL, cholesteryl hydroxyperoxy-octade-cadienoate (Chol-HPODE) and cholesteryl hydroxyl-octadecadienoate (Chol-HODE) were detected as the main oxidation products. Chol-HPODE was reported to inactivate platelet-derived growth factor. The third phase is the decomposition phase where the hydroperoxides are converted to reactive aldehydes. These aldehydes react with lysine residues in apolipoprotein (apo) B-100, resulting in oxLDL, which has decreased affinity for the LDL receptor and increased affinity for scavenger receptors of subendothelial macrophages [7].

Oxidized LDL represents a variety of modifications of both the lipid and protein components of LDL that occur when ROS induce lipid peroxidation. This oxidation process is thought to occur mainly in the arterial wall, rather than in plasma. Although fully oxLDL are cleared from the circulation within minutes by the reticuloendothelial system, the presence of small amounts of minimally modified LDL denotes the presence of circulating oxLDL. Therefore, the measurable circulating plasma levels of oxLDL represent only a small fraction of total LDL [8]. However, oxLDL antibodies are present in the circulation and can be readily measured. In the normal arterial wall without evidence of atherosclerosis, oxLDL levels are very low but in the early stages of atherosclerosis, oxLDL are clearly present. Although concentrations of oxLDL in the arterial wall are not measurable, circulating levels of oxLDL or oxLDL antibodies are theoretically the biomarker of total oxLDL, and consequently of total atherosclerosis burden [9].

Currently, a directly image oxLDL in human arteries is unavailable [10]. Yet, several specific oxLDL assays based on monoclonal antibodies have been developed since the 1990s, when clinical studies established the strong relationship of circulating oxLDL with cardiovascular diseases. These antibodies can bind unique oxidation-specific epitopes but the methods are not easily comparable, as they have different binding epitopes. More recently enzyme-linked immunoabsorbent assay (ELISA) methods to measure plasma levels of oxLDL are commercially available [11-13]. Oxidized phosphatidylcholines (oxPC) are produced after lipid oxidation and promote the expression of monocyte chemoattractant protein-1 (MCP-1) in endothelial cells and oxLDL recognition by macrophage scavenger receptors, mainly cluster of differentiation (CD) 36. In the first of the above mentioned ELISA methods, the murine immunoglobulin (Ig)M monoclonal antibody DLH3 recognizes oxPC epitopes and uses isolated LDL rather than plasma to measure oxLDL [14]. Another IgM monoclonal antibody, the E06, recognizes phosphorylcholine, the hydrophilic moiety in phosphatidylcholines, and by design this second method is independent of LDL cholesterol or apoB levels [15,16]. Finally, the third method uses the antibody 4E6 which binds to aldehydes-modified lysine groups on LDL. OxLDL levels measured with this method are

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

closely correlated with total LDL-cholesterol levels, and this may limit its clinical utility [17]. It is clear that these three assays use antibodies detecting different epitopes and they are set up in different formats and units of measurement. Thus, their results are not easily comparable, limiting the interpretation of the results in clinical studies that assessed plasma levels of oxLDL with different essays. For this reason Tsimikas et al. have suggested that investigators should present their data by linking their antibody to the type of oxLDL they have measured (i.e. “oxLDL-E06” for the E06 antibody) [8].

3. Oxidized LDL and cardiovascular risk

The majority of cardiovascular diseases are linked to the atherosclerosis process. One of the most important steps in this cascade is the transfer of oxLDL across the endothelium into the arterial wall [18]. This probably takes place at sites of endothelial rupture, induced by oxLDL itself as well as by physical forces and inflammation. OxLDL can damage the continuity of endothelial wall and further induce the expression of adhesion molecules such as MCP-1 and the macrophage colony stimulating factor [19]. Therefore, monocytes are activated and attached together with T lymphocytes on the surface of the endothelial cells. Subsequently, leucocytes as well as endothelial and smooth muscle cells secrete growth factors, which cause chemoattraction and, thus, the enhanced migration of monocytes and leucocytes into subendothelium. Modified monocytes form macrophages, which generate ROS that contribute to the conversion of oxLDL into highly oxidized particles.

This form of LDL is considered the most atherogenic and is taken up by macrophages to form the foam cells, which can secrete growth factors and, therefore, inducing smooth muscle cells migration and proliferation into the intima. Thus, the initial lesion, i.e. the fatty streak, is converted to a more advanced lesion with a fibrous cap that covers the lipid rich core. In acute coronary

syndromes, some of these plaques (vulnerable plaques) are thinner than the stable plaques, and more prone to rupture. A ruptured plaque is the nidus for thrombus formation and, therefore, for arterial lumen occlusion [20,21].

Beyond their crucial role in the formation of the atherosclerotic plaque, oxLDL seems to affect other aspect of the atherogenic process. For instance, endothelial dysfunction is clearly promoted by oxLDL. Apoptosis, a process in endothelial and smooth muscle cells that contributes to plaque vulnerability, seems to be affected by oxLDL and their products, such as phosphatidylcholine and oxysterols [22]. Also, oxLDL promotes thrombus formation by inducing the release of tissue factor by both endothelial cells and smooth muscle cells, and further stimulates the coagulation cascade by reducing thrombomodulin transcription, suppressing protein C activation and modulating tissue factor pathway inhibitor [7]. In addition, oxLDL increases expression of matrix metalloproteinase-9, which causes vascular remodeling and rupture of the fibrous cap in the atherosclerotic lesions [23].

Elevated plasma oxLDL levels have been reported in patients with coronary artery disease (CAD), carotid atheromatosis, and chronic hemodialysis. However, since oxidation of LDL is mediated by several risk factors and present in both early and late lesions, there is no clear evidence that oxLDL can be used as a marker of preclinical atherosclerosis. Nevertheless, in asymptomatic individuals, elevated oxLDL levels have been associated with increased carotid intima-media thickness and familial hypercholesterolemia [24]. Moreover, some clinical studies have shown an inverse correlation between levels of oxLDL and HDL cholesterol [7].

The association of plasma oxLDL with the presence and the severity of CAD has been established from many clinical studies with the use of the ELISA procedures mentioned above. Several reports have shown an increase in oxLDL levels in the acute phase immediately after acute myocardial infarction, cerebral infarction, or percutaneous transluminal coronary angiography (PTCA) procedure [25]. One possible explanation for this temporal increase is that oxLDL can be

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

released from the ruptured fibrous cap of the atherosclerotic lesions at the time of occurrence of infarction. Moreover, this observation suggests that plasma oxLDL could reflect the conditions of atherosclerotic lesions and vulnerability of the plaque.

This association was previously documented in cross-sectional studies showing a correlation among severity of acute coronary syndrome and levels of plasma oxLDL. Hayashida et al. demonstrated elevated levels of serum soluble lectin-like oxidized LDL receptor-1 (the endothelial receptor for oxLDL) in patients with acute coronary syndromes, suggesting their potential prognostic role [26]. Ehara et al. also reported that circulating oxLDL-DLH3 levels were elevated in acute coronary syndromes and that this was correlated with the presence of oxLDL in atherectomy material removed after PTCA [27]. In addition, in a follow-up study, Tsimikas et al. suggested that iatrogenic rupture of the plaque during PTCA increases plasma levels of oxLDL-E06 [16]. In this latter study, a strong correlation was documented between lipoprotein(a) [Lp(a)] and oxLDL-E06 levels, supporting the novel observation from the same group that Lp(a) ultimately binds most of the oxidized phospholipids measured by monoclonal antibody oxLDL-E06. These authors suggested that Lp(a) may be a part of the innate immune system, having a role in clearing proinflammatory oxidized phospholipids; yet, when Lp(a) levels are elevated, as under oxidative stress, this lipoprotein may become an atherogenic molecule in the arterial wall [28].

The same research group has also recently confirmed the association of circulating levels of oxLDL with stable CAD, a relationship which had been already reported in previous studies [29-31]. In a population of 504 patients undergoing coronary angiography for stable CAD, they reported a close correlation of oxLDL/apoB-100 ratio with the presence and the extent of coronary atherosclerosis [28]. Interestingly, a close correlation between Lp(a) and the above mentioned ratio was found in this study; nevertheless, in patients under 60 years old, oxLDL/apoB levels were independent of Lp(a), suggesting that oxLDL may mediate atherogenicity beyond its association with Lp(a).

In the stent implantation era, restenosis is considered a serious complication, although it has been significantly reduced using drug-eluting stents. There are conflicted results about the usefulness of oxLDL in predicting in stent restenosis and secondary cardiovascular events after a successful PTCA. Naruko et al. enrolled 102 patients with acute myocardial infarction and showed that high levels of oxLDL-DLH3 prior to discharge were correlated with highly percentages of restenosis [32]. On the other hand, Braun and colleagues in 687 patients who suffered from unstable and stable angina or myocardial infarction, did not show a significant correlation between oxLDL-4E6 levels and cardiovascular outcomes, including cardiovascular death, myocardial infarction or angiographically-determined restenosis [33]. In consistent to these findings, Segev et al. have shown that oxLDL-E06 levels, despite an increase after uncomplicated PTCA for stable angina, were not associated with restenosis, in a 6-month angiographic follow-up study [34].

4. Oxidized LDL in patients with type 2 diabetes mellitus

Recent evidences suggest that diabetic atherosclerosis cannot simply be attributed to the adverse lipid profile of these patients, but is mainly an oxidation and inflammation mediated process. It is well known that individuals with type-2 DM exhibit enhanced LDL oxidizability, leading to accelerated atherosclerosis. Glycemia itself induces oxidative stress and advanced glycation end products, formed by glucose-induced modification of proteins, and further acts as ligands for multiple receptors, such as the lectin-like oxidized LDL receptor-1 (LOX-1), inducing oxidative stress, inflammation and vascular dysfunction in diabetes. LOX-1 has been identified as the major oxLDL receptor that is present primarily in the endothelial cells; it has been found up-regulated in the vascular endothelium of diabetic animals and seems to play an important role in the pathogenesis of hypertension, diabetes and atherosclerosis (Figure 1).

Also, oxLDL interacts with β 2-glycoprotein I (β 2GPI), and oxLDL/ β 2GPI complexes have been considered as putative autoantigens in the autoimmune-mediated atherosclerotic vascular

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

disease. Tabuchi et al. [35] reported a potent interaction of C-reactive protein with oxLDL/ β 2GPI complexes and its association with arterial inflammation, hyperglycemia and hypercholesterolemia in patients with diabetes mellitus. Further, an increase in the *in vivo* LDL oxidation has been clearly shown in patients with type-2 diabetes, as reflected by the higher prevalence of highly oxidized LDL [36]. The association between glycemia and LDL oxidation is in agreement with the observation that even in healthy individuals transiently increased plasma glucose levels correlate with a higher susceptibility of *in vitro* oxidation of LDL [37].

Yet, oxLDL themselves may also promote glycemia and the development of diabetes. Recent data from the CARDIA study showed that in healthy young individuals high concentrations of oxLDL were associated with abdominal obesity, hypertriglyceridemia and hyperglycemia [38], which are essential components of the metabolic syndrome. Notably, subjects at the highest quartile of oxLDL concentrations had a threefold higher risk for the development of metabolic syndrome compared to those who were at lowest quartile during the 5-year follow up. In addition, in a recent clinical study that enrolled women having normal glucose levels, impaired glucose tolerance, impaired fasting glucose or diabetes type-2, levels of oxLDL were independent predictors for the development of type- 2 diabetes after the 6-year follow-up [39]. This may be explained by the fact that oxLDL can reduce the insulin signaling [40] as well as the glucose uptake [41].

On clinical grounds, the role of oxLDL as predictor of increased cardiovascular morbidity and mortality in patients with type-2 diabetes has not been clearly delineated. Data from the Health, Aging and Body Composition study, including 3,033 elderly individuals, failed to demonstrate a significant association between oxLDL levels and total cardiovascular risk. Nevertheless, subjects with high oxLDL levels showed a trend to suffer more frequently of acute myocardial infarction [42]. Luoma et al. further reported that oxLDL autoantibodies were not predictive of severe chest pain attacks in patients with type-2 diabetes and CAD who were part of this large cohort. By contrast, a predictive role of oxLDL for cardiac events in patients with diabetes type-2 was demonstrated by Shimada et al. [43]. They found in patients with type-2 diabetes and

angiographically documented CAD that high levels of oxLDL were an independent and significant predictor of cardiovascular events. In line with these findings, Stephens et al. [44] reported a significant association between plasma oxLDL:LDL ratio and CAD status in a cross sectional study of 3,012 middle-aged men with type-2 diabetes

Although the correlation with hard clinical end points seems to be weak, the association of with softer end points, such as surrogate markers of atherosclerosis, is more stronger. A clinical study, which included patients with type-2 DM and control subjects, suggested that in patients with long duration of the disease the levels of oxLDL were significantly higher, and that the ankle-brachial index was lower than in control or newly diagnosed patients [45]. Similarly, greater intima-media thickness (IMT) of common carotid artery was correlated with higher levels of oxLDL [45]. Data from the Chennai Urban Rural Epidemiology Study showed a strong association between oxLDL and IMT, even after adjusting for age, sex, and glucose intolerance. Ujihara et al. [46] further investigated the association between diabetic nephropathy and high levels of oxLDL in patients with type-2 DM. They found that patients with macroalbuminuria had higher values of oxLDL in comparison to the other patients of the cohort with either microalbuminuria or normal renal function. Similar findings were reported by Hsu et al [47]: in comparison to controls, increased titers of oxLDL antibodies were found in patients with type-2 DM and macrovascular disease, but not in those without macrovascular disease.

OxLDL has also been implicated in the hypertrophy of adipocytes from lipid accumulation and proliferation of adipose tissue [48]. It has been also reported that oxLDL may modulate the production of adiponectin, which is able to reduce the excess ROS production in hyperglycemic states, an effect that has implications for vascular protection in diabetes [49]. In addition, oxLDL may impair triglyceride storage and secretion [50]. To complete this circle of associations between LDL peroxidation and obesity, it has been proposed that the increase in adipose tissue may promote the synthesis of oxLDL, by either increasing production of arachidonate-5-lipoxygenase which catalyzes LDL oxidation, or by decreasing production of superoxide dismutase, which prevents

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

LDL oxidation [48]. However, a more relevant pathophysiologic explanation may be the increased production by the adipose tissue of small dense LDL, which is reputedly more prone to oxidation than buoyant LDL particles [51]. Both diabetes and the metabolic syndrome may promote LDL oxidation through glycemia, development of end-glycation products and increased adiposity. On the other hand, oxLDL may further deteriorate insulin resistance and promote the proliferation of adipocytes. Notably, Scheffer et al [52] have shown that smaller LDL size was associated with increased levels of oxidized LDL, providing additional evidence for the role of small, dense LDL in the etiology of atherosclerosis in diabetes.

5. Formation of small, dense LDL

LDL comprises multiple subclasses with discrete size and density, different physicochemical composition and metabolic behaviour. Based on their characteristic appearance in analytical ultracentrifugation and gradient gel electrophoresis, up to seven distinct subclasses have been defined. It has been suggested that there are parallel metabolic channels within the delipidation cascade from VLDL to LDL [53] and a metabolic relationship between large VLDL particles and small LDL particles has been demonstrated using stable isotopes in subjects with a predominance of small, dense LDL [54]. These studies have not yet identified the specific precursors of individual LDL subclasses; however there are data from animal models suggesting that separate pathways may be responsible for the generation of distinct LDL particles [55]. Dietary intervention studies also demonstrated inverse correlations between changes in large and small LDL, as well as between changes in medium sized and very small LDL, which raise the possibility of precursor-product relationships between distinct LDL subclasses [56].

Activity of lipolytic enzymes is related to the size of LDL particles. A significant inverse relationship between post-heparin lipoprotein lipase activity and small, dense LDL has been demonstrated and induction of lipoprotein lipase by high fat diet was associated with an increase of

large LDL and decrease of small, dense LDL. Reduced activity of lipoprotein lipase and increased activity of hepatic lipase has been shown in subjects with a predominance of small, dense LDL particles [57]. Hepatic lipase has a higher affinity for LDL than lipoprotein lipase and is positively correlated with plasma triglycerides, apoB, mass of large VLDL and small, dense LDL, but not with the mass of large LDL [58], suggesting a central role for hepatic lipase in the lipolytic conversion of these particles.

Triglyceridaemia seems to be the main determinant of LDL subclass distribution [59]. In fact, the formation of small, dense LDL particles is mostly observed in hypertriglyceridemic state, with an increased transfer of triglycerides from triglyceride-rich lipoproteins to LDL and HDL particles, in exchange of cholesteryl esters through the action of cholesteryl esters transfer protein [60]. This phenomenon leads to the generation of VLDL particles enriched in cholesteryl esters and smaller, triglyceride-rich LDL particles that are good substrates for hepatic lipase. As a consequence, predictive value of small, dense LDL is usually reduced when triglycerides levels are taken into account [61]. For example, in a published analysis from the EPIC-Norfolk prospective population study, predictive power for cardiovascular events of LDL particle number and size was lost after adjustment for HDL-cholesterol and triglycerides levels [62].

6. Small, dense LDL and cardiovascular risk

Several reasons have been suggested to explain the enhanced atherogenicity of small, dense LDL. These particles are taken up more easily by arterial tissue than larger LDL [63], suggesting greater transendothelial transport. In addition, small, dense LDL have decreased receptor-mediated uptake and increased proteoglycan binding [64]. Sialic acid, due to its exposure at the LDL surface, plays a determinant role in the *in vitro* association of LDL with the polyanionic proteoglycans [65] and it has been shown that sialic acid content of LDL particles of subjects with the predominance of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

small, dense LDL is reduced. Further, oxidative susceptibility increases and antioxidant concentrations decreases with decreasing LDL size [66]. Altered properties of the surface lipid layer associated with reduced content of free cholesterol [67] and increased content of polyunsaturated fatty acids [68] might also contribute to enhanced oxidative susceptibility of small dense LDL.

To date, the association of LDL size with cardiovascular diseases has been tested in over fifty studies, including cross-sectional and prospective epidemiologic, as well as clinical intervention trials; these studies overall suggest that the quality of LDL exerts a direct influence on cardiovascular risk. Due to previously described atherogenic properties, the predominance of small, dense LDL has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. It has also been shown that even small increases in the concentration of these particles may substantially contribute to the determination of total cardiovascular risk [69]. Other studies have investigated if the therapeutic modification of LDL size may be significantly associated with reduced cardiovascular risk. Such investigations used arteriographic changes as outcome variables and have reported that benefit was concentrated in patients with a predominance of small, dense LDL who received treatment that tend to reduce the amount of such particles [70-72].

These findings overall suggest that the therapeutic modification of LDL size may be significantly associated with reduced cardiovascular risk, even after multivariate adjustment for confounding factors. In addition, it has been reported [73], although not directly demonstrated, that the modulation of LDL size with fibrates probably contributed to the reduction of cardiovascular risk in large clinical trials [74-76]. Yet, it cannot be fully excluded that the increased cardiovascular risk associated with smaller LDL size may also be a consequence of the broader pathophysiology of which small, dense LDL are a part (e.g. high triglycerides, low HDL-cholesterol, increased LDL particle number, obesity, insulin resistance, diabetes, metabolic syndrome) [77-80].

7. Small, dense LDL and type-2 diabetes

Small, dense LDL represent one the main dislipidemic features in type-2 diabetes [81]. Subjects with a predominance of small dense LDL have a greater than two fold increased risk for developing type-2 diabetes independently of age, sex, glucose tolerance and body mass index, and it has been calculated that an increase in LDL size may be associated with about a 16% decrease in the risk of developing diabetes [82]. Subjects with the insulin resistance syndrome have an elevated prevalence of small, dense LDL [83] and this has been confirmed in both men and women with type-2 diabetes [84,85]. In addition, using a euglycemic clamp technique to categorise individuals as insulin-sensitive, insulin-resistant, or with diabetes, more severe states of insulin resistance were associated with smaller LDL size [86].

We have investigated the clinical significance of LDL size and LDL subclasses in patients with type-2 diabetes: those with manifest CAD had decreased LDL size and increased small, dense LDL particles as compared to subjects without established CAD. Multivariate analysis revealed that LDL size was the strongest marker of CAD as compared to other established cardiovascular risk factors, including plasma lipids and lipoproteins [87]. Increased IMT is considered a reliable surrogate marker of early atherosclerosis and it has been shown to significantly correlate with the presence of CAD and to predict coronary events [88-90]. In the previously mentioned study [87] LDL size was significantly associated with carotid IMT and LDL size was the second strongest predictor of IMT when compared to nine other cardiovascular risk factors, and the strongest of all lipid parameters. Thus, small, dense LDL is a key feature of subjects with type-2 diabetes and seems further to represent a strong marker of their clinical and subclinical atherosclerosis.

Hypolipidemic treatments are able to favourably modulate LDL size and subclasses in patients with type-2 diabetes but the effects are varying among the different agents (Table 1). Notably, in the “Diabetes Atherosclerosis Intervention Study” [91] the therapeutical modulation of LDL size by fenofibrate was significantly associated with reduced cardiovascular risk at univariate analysis; in addition, using multivariate analyses with adjustments for confounding factors, changes

1
2 in LDL size were strong predictors for cardiovascular events. Yet, although fibrates are more
3
4 powerful than statins in improving LDL size and subclasses, existing evidence suggest that statins
5
6 are more powerful agents in reducing hard clinical end points (i.e. cardiovascular morbidity and
7
8 mortality). In the same context, while fenofibrate seems to be the best fibrate in lowering small
9
10 dense LDL, the FIELD study [92] showed no significant reduction in the primary end point in
11
12 patients with type-2 diabetes who were randomised to receive fenofibrate or placebo.
13
14
15
16
17
18
19
20

21 **8. Conclusions**

22
23 The most important link between lipid metabolism and inflammation is based on the
24
25 formation of foam cells (first step of plaque generation) from altered, oxidized LDL [93]. Yet, LDL
26
27 are very heterogeneous particles, with distinct subclasses that differ in size, density,
28
29 physicochemical composition, metabolic and oxidative behaviour, as well as atherogenicity [94].
30
31 Increasing evidence suggests that the “quality” of LDL has a direct influence on cardiovascular
32
33 risk, with smaller, more dense LDL particles being more susceptible to oxidation and greatly
34
35 atherogenic [95].
36
37
38

39 The inflammation process is induced from oxidized lipoproteins, mainly oxLDL, that are
40
41 independent predictors of the progression of the atherosclerosis cascade, possibly by binding
42
43 monocytes to the endothelium [96]. Additionally, oxLDL seems to be responsible for the expression
44
45 of pro-inflammatory genes in the subendothelium of vascular bed, including leukocyte adhesion
46
47 molecules (e.g. intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and P-
48
49 selectin), chemotactic molecules, (e.g. MCP-1) and mitogenic growth factors, such as the
50
51 macrophage-colony-stimulating factor, which has a pivotal role in the recruitment and activation
52
53 of inflammatory cells in the vessel wall [97,98]. Furthermore, oxLDL has a potential role in the
54
55 formation of reactive aldehyde and phospholipid species with proinflammatory properties, such as
56
57 the lysophosphatidylcholine [99]. In patients with type-2 diabetes hyperglycemia enhances the
58
59
60

oxidative stress, further modifying LDL into oxLDL. In such patients the decreased antioxidant activity is also linked to the lower plasma levels of anticoagulant proteins, as well as to the increased levels of hydroperoxides [100,101].

Yet, the relationship between autoantibodies to oxLDL and atherosclerosis remains controversial. There are studies showing high levels of autoantibodies to oxLDL in subjects with coronary artery disease, carotid atherosclerosis or peripheral arterial disease [102,103]. Current evidences support the concept that IgG autoantibodies are associated with atherogenesis enhancement while IgM have a natural protective role [104]. Circulating IgM autoantibodies have been found in plasma of apparent healthy subjects without any atherosclerosis manifestation [105]. It has been also demonstrated a positive correlation of IgG autoantibodies to angiographically documented coronary artery disease and an inverse association of IgM with it [106]. Further, in patients with type-2 diabetes high levels of IgG autoantibodies were not associated with subclinical atherosclerosis, but with manifest atherosclerotic lesions [45].

Therefore, oxidized and small, dense LDL seems to have a synergistic impact on cardiovascular risk (**Figure 2**), with a greater importance in patients at higher-risk, such as those with type-2 diabetes. Increased levels of oxidized and small, dense LDL levels are a feature of patients with type-2 diabetes and small, dense LDL have been shown to be good predictor of future cardiovascular events, even after multivariate adjustment for confounding factors. On the other hand, although the association of oxidized LDL with surrogate markers of atherosclerosis is consistent, the correlation with hard clinical end points seems to be smaller.

In addition, lack of availability of easy, cheap and reproducible essays for measurement of oxidized and, particularly, small, dense LDL have reduced their assessment in large clinical end-points trials. However, on the basis of available data, the therapeutic modulation of small, dense LDL is significantly associated with reduced cardiovascular risk, even after multivariate adjustment for confounding factors. Since small, dense LDL are difficult to be measured in non-specialized laboratories, in the last years alternative approaches have included the use of lipid indices as their

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

surrogate markers; yet, recent studies have shown that these lipid indices are not good predictors of small, dense LDL [107] and, therefore, their use should be discouraged.

In conclusion, on the basis of available data, the routine measurement of oxidized and small, dense LDL in patients with type-2 diabetes cannot be recommended in daily clinical practice so far. Yet, their measurement is strongly encouraged, in order to better understand their role on cardiovascular risk of patients with type-2 diabetes.

For Peer Review Only

AUTHORS' CONTRIBUTIONS

Manfredi Rizzo: Concept/design, Data analysis/interpretation, Drafting article, Critical revision of article, Approval of article.

Kaspar Berneis: Concept/design, Data analysis/interpretation, Drafting article, Critical revision of article, Approval of article.

Spyridon Koulouris: Drafting article, Critical revision of article, Approval of article.

Socrates Pastromas: Concept/design, Data analysis/interpretation, Drafting article, Critical revision of article, Approval of article.

Giovam Battista Rini: Drafting article, Critical revision of article, Approval of article.

Dimitrios Sakellariou: Drafting article, Critical revision of article, Approval of article.

Antonis S. Manolis: Drafting article, Critical revision of article, Approval of article.

REFERENCES

1) Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002 May 15;287(19):2570-81.

2) Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004 Jun;45(6):993-1007

3) Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915-24

4) Rizzo M, Kotur-Stevuljevic J, Berneis K, Spinaz G, Rini GB, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Vekic J. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res. 2009 May;153(5):217-23

5) Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):150-9

6) Heinecke J. W. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr. Opin. Lipidol 1997;8: 268–274

7) Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001 Oct;15(12):2073-84

8) Tsimikas S, Witztum JL. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 2001;103:1930–2

9) Tsimikas S, Shortal BP, Witztum JL, et al. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic

- 1
2
3 lesions rich in oxidized LDL and is highly sensitive to their regression. *Arterioscler*
4
5 *Thromb Vasc Biol* 2000;20:689–97.
6
7
8 10) Torzewski M, Shaw PX, Han KR, et al. Reduced in vivo aortic uptake of radiolabeled
9
10 oxidation-specific antibodies reflects changes in plaque composition consistent with plaque
11
12 stabilization. *Arterioscler Thromb Vasc Biol* 2004; 24:2307–2312
13
14
15 11) Holvoet P, Perez G, Zhao Z, et al. Malondialdehyde-modified low density lipoproteins in
16
17 patients with atherosclerotic disease. *J Clin Invest* 1995;95:2611–9.
18
19
20 12) Itabe H, Yamamoto H, Imanaka T, et al. Sensitive detection of oxidatively modified low
21
22 density lipoprotein using a monoclonal antibody. *J Lipid Res* 1996;37:45–53.
23
24
25 13) Palinski W, Hörkkö S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of
26
27 oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of
28
29 oxidized low density lipoprotein in human plasma. *J Clin Invest* 1996;98:800–14.
30
31
32 14) Itabe H, Takeshima E, Iwasaki H, et al. A monoclonal antibody against oxidized
33
34 lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized
35
36 phosphatidylcholines and polypeptides. *J Biol Chem* 1994; 269:15274–15279
37
38
39 15) Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of
40
41 oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
42
43 *J Am Coll Cardiol* 2003;41:360–70.
44
45
46 16) Tsimikas S, Lau HK, Han KR, et al.: Percutaneous coronary intervention results in acute
47
48 increases in oxidized phospholipids and lipoprotein(a): short-term and long term
49
50 immunologic responses to oxidized low-density lipoprotein. *Circulation* 2004; 109:3164–
51
52 3170
53
54
55 17) Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB. Is plasma oxidized low-density
56
57 lipoprotein, measured with the widely used antibody 4E6, an independent predictor of
58
59 coronary heart disease among U.S. men and women. *J Am Coll Cardiol*. 2006;48:973-9.
60

- 18) Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. *Postgrad Med J*. 2008 Jul;84(993):368-71.
- 19) Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. *Proc Natl Acad Sci USA*. 1990;87:5134-5138.
- 20) Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. *Arterioscler Thromb Vasc Biol*. 2005 Jan;25(1):29-38
- 21) Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. *Am J Cardiol*. 2000 Oct 19;86(8B):3J-8J
- 22) Björkerud B, Björkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. *Arterioscler Thromb Vasc Biol*. 1996;16:416-24
- 23) Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. *Circulation* 1999;99:993-8.
- 24) Liu ML, Ylitalo K, Salonen R, et al. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. *Arterioscler Thromb Vasc Biol* 2004;24:1492-7
- 25) Itabe H. Circulating Oxidized Lipoproteins and Cardiovascular Risk. *Current Cardiovascular Risk Reports* 2009;3:18-22.
- 26) Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, Kita T. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. *Circulation*. 2005;112:812-8

- 27) Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. *Circulation*. 2001;103:1955-60
- 28) Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. *N Engl J Med* 2005;353:46–57.
- 29) Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 2001; 21:844–848.
- 30) Suzuki T, Kohno H, Hasegawa A, et al. Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. *Clin Biochem* 2002; 35:347–353.
- 31) Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low density lipoprotein levels: A biochemical risk marker for coronary heart disease. *Arterioscler Thromb Vasc Biol* 2000; 20: 2243–2247
- 32) Naruko T, Ueda M, Ehara S, Itoh A, Haze K, Shirai N, Ikura Y, Ohsawa M, Itabe H, Kobayashi Y, Yamagishi H, Yoshiyama M, Yoshikawa J, Becker AE. Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. *Arterioscler Thromb Vasc Biol*. 2006;26:877-83.
- 33) Braun S, Ndrepepa G, von Beckerath N, Mehilli J, Gorchakova O, Vogt W, Schömig A, Kastrati A. Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. *Am Heart J*. 2005; 150:550-6.
- 34) Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S. Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

patients undergoing percutaneous coronary intervention for stable angina. *Am Heart J* 2005; 150:1007–1014

35) Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, Kasahara J, Kume N, Lopez LR, Mitsudo K, Nobuyoshi M, Yasuda T, Kita T, Makino H, Matsuura E. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. *J Lipid Res.* 2007 ;48:768-81

36) Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. *Diabetes* 2004;53:1068–1073

37) Chen NG, Azhar S, Abbasi F, Carantoni M, Reaven GM. The relationship between plasma glucose and insulin responses to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. *Atherosclerosis* 2000;152:203–208

38) Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. *JAMA.* 2008;299:2287-93.

39) Garrido-Sánchez L, Cardona F, García-Fuentes E, Rojo-Martínez G, Gómez-Zumaquero JM, Picón MJ, Soriguer F, Tinahones FJ. Anti-oxidized low-density lipoprotein antibody levels are associated with the development of type 2 diabetes mellitus. *Eur J Clin Invest.* 2008 ;38:615-21.

40) Mazière C, Morliere P, Santus R, et al. Inhibition of insulin signaling by oxidized low density lipoprotein: protective effect of the antioxidant vitamin E. *Atherosclerosis* 2004;175:23–30.

- 41) Maddux BA, See W, Lawrence JC Jr, Goldfine AL, Goldfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of alpha-lipoic acid. *Diabetes* 2001;50:404–410
- 42) Holvoet P, Harris TB, Tracy RP et al.: Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging and Body Composition study. *Arterioscler. Thromb. Vasc. Biol.* 2003;23:1444–1448
- 43) Hsu RM, Devaraj S, Jialal I. Autoantibodies to oxidized low-density lipoprotein in patients with type 2 diabetes mellitus. *Clin Chim Acta.* 2002 Mar;317(1-2):145-50.
- 44) Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, Kume A, et al. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. *Diabetes Care* 2004;27:843-4
- 45) Piarulli F, Lapolla A, Sartore G, Rossetti C, Bax G, Noale M, Minicuci N, Fiore C, Marchioro L, Manzato E, Fedele D. Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes. *Diabetes Care* 2005;28(3):653-7.
- 46) Gokulakrishnan K, Deepa R, Velmurugan K, Ravikumar R, Karkuzhali K, Mohan V. Oxidized low-density lipoprotein and intimal medial thickness in subjects with glucose intolerance: the Chennai Urban Rural Epidemiology Study-25. *Metabolism.* 2007;56:245-50.
- 47) Ujihara N, Sakka Y, Takeda M, Hirayama M, Ishii A, Tomonaga O, Babazono T, Takahashi C, Yamashita K, Iwamoto Y. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. *Diabetes Res Clin Pract.* 2002 Nov;58(2):109-14.
- 48) Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H, Ohsugi M, Tobe K, Kadowaki T, Nagai R, Sugiura S. Adipogenesis in obesity requires close interplay

- between differentiating adipocytes, stromal cells, and blood vessels *Diabetes*. 2007; 56:1517-26.
- 49) Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough K, Scalia R, Goldstein BJ. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. *Diabetes* 2006;55:1840–1846.
- 50) Krauss RM, Burke DJ: Identification of multiple subclasses of plasma low density lipoproteins in normal humans. *J. Lipid. Res.* 1982;23:97–104.
- 51) Lamarche B, Tchernof A, Moorjani S et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. *Circulation* 1997; 95:69–75.
- 52) Scheffer PG, Bos G, Volwater HG, Dekker JM, Heine RJ, Teerlink T (2003) Association of LDL Size with In Vitro Oxidizability and Plasma Levels of In Vivo Oxidized LDL in Type 2 Diabetic Patients. *Diabetic Med* 20:563-567
- 53) Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. *J Lipid Res* 2002; 43: 1363-1379.
- 54) Krauss RM, Hellerstein MK, Neese RA, Blanche PJ, La Belle M, Shames DM. Altered metabolism of large low density lipoproteins in subjects with predominance of small low density lipoproteins. *Circulation* 1995; 92:1-102.
- 55) Rizzo M, Taylor JM, Barbagallo CM, Berneis K, Blanche PJ, Krauss RM. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. *Arterioscler Thromb Vasc Biol* 2004; 24:141-146.
- 56) Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia. *Arterioscler Thromb Vasc Biol* 2005; 25:2265-72.

- 1
2
3 57) Jansen H, Hop W, van Tol A, Bruschke AV, Birkenhager JC. Hepatic lipase and
4
5 lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern
6
7 in human subjects with coronary heart disease. *Atherosclerosis* 1994; 107:45-54.
8
9
10 58) Campos H, Dreon DM, Krauss RM. Associations of hepatic and lipoprotein lipase
11
12 activities with changes in dietary composition and low density lipoprotein subclasses. *J*
13
14 *Lipid Res* 1995; 36:462-472.
15
16
17 59) Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines
18
19 structure-composition in low and high density lipoproteins. *Arteriosclerosis* 1984; 4:225-
20
21 231.
22
23
24 60) Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Atherogenic role of
25
26 elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of
27
28 the degree of triglyceridemia. *Arterioscler Thromb Vasc Biol* 2001; 21:282-288.
29
30
31 61) Rizzo M, Berneis K. Who needs to care about small, dense low density lipoproteins? *Int J*
32
33 *Clin Pract* 2007; 61:1949-56.
34
35
36 62) El Harchaoui K, van der Steeg WA, Stroes ES et al. Value of low-density lipoprotein
37
38 particle number and size as predictors of coronary artery disease in apparently healthy men
39
40 and women: the EPIC-Norfolk Prospective Population Study. *J Am Coll Cardiol* 2007;
41
42 49:547-53.
43
44
45 63) Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions
46
47 and subfractions in the arterial wall, determined in an in vitro perfusion system.
48
49 *Atherosclerosis* 1996; 123:43-56.
50
51
52 64) Galeano NF, Al-Haidari M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low
53
54 density lipoprotein has increased affinity for LDL receptor-independent cell surface
55
56 binding sites: a potential mechanism for increased atherogenicity. *J Lipid Res* 1998;
57
58 39:1263-1273.
59
60

- 65) Camejo G, Lopez A, Lopez F, Quinones J. Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. *Atherosclerosis* 1985; 55:93-105.
- 66) Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. *Am J Med* 2001; 110:103-110.
- 67) Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. *Atherosclerosis* 1992; 93:189-199.
- 68) de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. *Arterioscler Thromb* 1991; 11:298-306.
- 69) St Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the longterm risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. *Arterioscler Thromb Vasc Biol* 2005; 25:553-9.
- 70) Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. *Am J Cardiol*. 2002;90(2):89-94.
- 71) Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. *Circulation* 1996; 94:2146-2153
- 72) Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. *Circulation* 1999; 99:1959-64.

- 73) Marais AD. Therapeutic modulation of low-density lipoprotein size. *Curr Opin Lipidol* 2000; 11:597–602.
- 74) Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. *Circulation* 1992; 85:37-45.
- 75) Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and the treatment with gemfibrozil. Experience from the Helsinki Heart Study. *Circulation* 1995; 92:1779-1785.
- 76) Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trials Study Group. *N Engl J Med* 1999; 341:410-418.
- 77) Sacks FM and Campos H. Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal. *J Clin Endocr Metab* 2003; 88:4525–4532.
- 78) Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. *Diabetes Metab* 1999; 25:199-211.
- 79) Lada AT, Rudel LL. Associations of low density lipoprotein particle composition with atherogenicity. *Curr Opin Lipidol* 2004; 15:19-24.
- 80) Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. *Curr Atheroscler Rep* 2004; 6:381-7.
- 81) Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. *Diab Care* 2004; 27:1496-1504.

82) Austin MA, Mykkanen L, Kuusisto J et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. *Circulation* 92:1770-8, 1995

83) Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. *J Clin Invest.* 1993;92:141-146.

84) Selby JV, Austin MA, Newman B et al. LDL subclass phenotypes and the insulin resistance syndrome in women. *Circulation* 88:381-7, 1993

85) Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. *Arterioscler Thromb.* 1992; 12:1496-502.

86) Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. *Diabetes* 2003; 52:453-62.

87) Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. *Metabolism.* 2005;54:227-234.

88) Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. *Am J Epidemiol* 146:483-94, 1997

89) Craven TE, Ryu JE, Espeland MA et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. *Circulation* 82:1230-42, 1990

- 90) Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR, 3rd. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. *Arterioscler Thromb* 11:1786-94, 1991
- 91) Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR; DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). *Circulation* 2003; 107:1733-7.
- 92) Keech A, Simes RJ, Barter P et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet* 2005; 366:1849-61
- 93) Albertini R, Moratti R, De Luca G. Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies. *Curr Mol Med* 2002;2:579-92.
- 94) Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. *Atherosclerosis* 1990;83:59-67.
- 95) Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? *Clin Lab* 2009; 55:421-429.
- 96) Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocytes endothelial interactions. *J Clin Invest* 1990;85:1260-6.
- 97) Palinski W, Witztum JL. Immune responses to oxidative neopeptides on LDL and phospholipids modulate the development of atherosclerosis. *J Intern Med* 2000; 247:371-380.
- 98) Berliner J, Navab M, Fogelman A, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. *J Clin Invest* 1995; 91:2488-2496.

- 99) Olofsson KE, Andersson L, Nilsson J, Bjorkbacka H. Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages. *Biochem Biophys Res Commun* 2008;370:348-352.
- 100) Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes *Diabetes* 1999;48:937-42.
- 101) De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattini G, Landolfi R, Patrono C, Davì G. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. *J Thromb Haemost* 2003;1:250-6.
- 102) Monaco C, Crea F, Piccoli G, Sommaria F, Cianflone D, Bordone R, Bellomo G, Maseri A. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease. Pathophysiological implications. *European Heart Journal* 2001;22::1572–1577.
- 103) Salonen JT, Nyssönen K, Salonen R, Porkkala-Saratho E, Tuomainen T-P, Diczfaluzi U, Björkhem I. Lipoprotein oxidation and progression of carotid atherosclerosis. *Circulation* 1997;95:840-845.
- 104) Nilsson J, Kovanen PT. Will autoantibodies help to determine severity and progression of atherosclerosis? *Curr Opin Lipidol* 2004; 15: 499–503.
- 105) Chen HW, Kuo CL, Huang CS, Kuo SJ, Liu CS. Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population. *Cardiology* 2008;110:252–259.
- 106) Tsimikas S, Brikalis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events, *J Lipid Res* 2007;48:425–433.

- 1
2
3
4 107) Décary S, et al, Assessment of the validity of the frequently used lipid indices for
5
6 predicting LDL peak particle diameter in a large cohort of 1955 normal and dyslipidemic
7
8 subjects, Clin Biochem (2009), doi:10.1016/j.clinbiochem.2009.11.010
9
10
11 108) Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses
12
13 modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115:477-
14
15 82.
16
17 109) Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P, Christ ER. Comparative
18
19 effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein
20
21 size and subclasses in patients with Type-2 diabetes. Expert Opin Pharmacother 2008;
22
23 9:343-49
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Therapeutic modulation of LDL size and subclasses by different agents in subjects with type-2 diabetes (as modified from **108,109**).

Authors	Year	Drug	Benefit
Winkler et al.	2002	Fluvastatin	Yes
Kazama et al.	2003	Pravastatin	No
Geiss et al.	2002	Simvastatin	No
Freed et al.	2002	Atorvastatin	No
Pontrelli et al.	2002	Atorvastatin	Yes
Wagner et al.	2003	Atorvastatin	Yes
Ikejiri et al.	2004	Atorvastatin	Yes
Frost et al., Geiss et al.	2001	Atorvastatin	No
Soedamah et al.	2003	Atorvastatin	No
Lahdenpera et al.	1993	Gemfibrozil	Yes
O’Neal et al.	1998	Gemfibrozil	Yes
Wagner et al.	2003	Gemfibrozil	Yes
Kazama et al.	2003	Bezafibrate	Yes
Kondo et al.	2004	Bezafibrate	No
Hayashi et al.	1998	Bezafibrate	Yes
Feher et al.	1999	Fenofibrate	Yes
Frost et al.	2001	Fenofibrate	Yes
Tan et al.	2001	Fenofibrate	Yes
Vakkilainen et al.	2003	Fenofibrate	Yes
Pan et al.	2002	Nicotinic acid	Yes
Pan et al.	2002	Nicotinic acid	Yes
Patti et al.	1999	Fish oil	No
Petersen et al.	2002	Fish oil	No
Mostad et al.	2007	Fish oil	No
Woodman et al.	2003	Fish oil (EPA)	No
Woodman et al.	2003	Fish oil (DHA)	Yes

Farnier et al.	2005	Ezetimibe	Yes
Winkler et al.	2002	Pioglitazone	Yes
Perez et al.	2004	Pioglitazone	Yes
Parhofer et al.	2005	Pioglitazone	Yes
Deeg et al.	2007	Pioglitazone	Yes
Berneis et al.	2008	Pioglitazone	Yes
Lautamaki et al.	2006	Rosiglitazone	No
Yu et al.	2006	Rosiglitazone	No
Albaladejo Oton et al.	2009	Rosiglitazone	No
Deeg et al.	2007	Rosiglitazone	No
Berneis et al.	2008	Rosiglitazone	No

EPA: eicosapentaenoic acid; DHA: docosaheptaenoic acid.

Figure 1. The vicious cycle between glycemia, LDL oxidation, advanced end glycation products (AEGs), lectin-like oxidized LDL receptor-1 (LOX-1) and atherosclerosis process in type-2 diabetes,

Figure 2. The synergistic role of oxidized and small, dense LDL in coronary artery disease.